Journal ArticleDOI
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
Whitley W. Aamodt,Teresa Waligorska,Junchao Shen,Thomas F. Tropea,Andrew Siderowf,Daniel Weintraub,Daniel Weintraub,Murray Grossman,David J. Irwin,David A. Wolk,Sharon X. Xie,John Q. Trojanowski,Leslie M. Shaw,Alice Chen-Plotkin +13 more
TLDR
In this paper, the authors used the Kruskal-Wallis rank test to determine whether plasma and cerebrospinal fluid NfLBP levels associated with motor or cognitive status in Parkinson's disease and predict future motor and cognitive decline in PD.Abstract:
BACKGROUND Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration. OBJECTIVES To determine whether plasma and CSF NfL (1) associate with motor or cognitive status in Parkinson's disease (PD) and (2) predict future motor or cognitive decline in PD. METHODS Six hundred and fifteen participants with neurodegenerative diseases, including 152 PD and 200 healthy control participants, provided a plasma and/or cerebrospinal fluid (CSF) NfL sample. Diagnostic groups were compared using the Kruskal-Wallis rank test. Within PD, cross-sectional associations between NfL and Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) and Mattis Dementia Rating Scale (DRS-2) scores were assessed by linear regression; longitudinal analyses were performed using linear mixed-effects models and Cox regression. RESULTS Plasma and CSF NfL levels correlated substantially (Spearman r = 0.64, P < 0.001); NfL was highest in neurocognitive disorders. PD participants with high plasma NfL were more likely to develop incident cognitive impairment (HR 5.34, P = 0.005). CONCLUSIONS Plasma NfL is a useful prognostic biomarker for PD, predicting clinical conversion to mild cognitive impairment or dementia. © 2021 International Parkinson and Movement Disorder Society.read more
Citations
More filters
Journal ArticleDOI
Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1
Zoë Y.G.J. van Lierop,Inge M.W. Verberk,Kees W.J. van Uffelen,Marleen J. A. Koel-Simmelink,Lisanne in ’t Veld,Joep Killestein,Charlotte E. Teunissen +6 more
TL;DR: Overall, the serum biomarkers tested were relatively unaffected by variations in sample handling, and confirm and expand on recently launched consensus standardized operating procedures.
Journal ArticleDOI
Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK‐PD Study)
Merve Uyar,Susanne Lezius,Carsten Buhmann,Monika Pötter-Nerger,Robert Schulz,Stephanie Meier,Christian Gerloff,Jens Kuhle,Chi-Un Choe +8 more
TL;DR: Diabetes is associated with incidence and prevalence of Parkinson's disease (PD) and glycated hemoglobin (HbA1c) levels have been linked with motor function and progression.
Journal ArticleDOI
Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases
Artur F. Schumacher-Schuh,Andréia Marisa Bieger,Wyllians Vendramini Borelli,Makayla Portley,Pauly Awad,Sara Bandres-Ciga +5 more
TL;DR: This review aims at providing a general overview on the current status of proteomic and metabolomic profiling in neurodegenerative diseases, and discusses the relevance of state-of-the-art metabolomics and proteomics approaches and their potential for biomarker discovery.
Journal ArticleDOI
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
Lucia Batzu,Silvia Rota,Abdul Hye,Amanda Heslegrave,Dhaval Trivedi,Lucy L. Gibson,Chloe Farrell,Pavlos Zinzalias,Alexandra Rizos,Henrik Zetterberg,K. Ray Chaudhuri,Dag Aarsland +11 more
TL;DR: In this article , the role of plasma tau phosphorylated at amino acid 181 (p-tau181) and plasma neurofilament light chain (NfL) as biomarkers of cognition in Parkinson's disease was investigated.
Journal ArticleDOI
Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
Lars Tönges,Carsten Buhmann,Stephan Klebe,Jochen Klucken,Eun-hea Kwon,K. Müller,David J. Pedrosa,Nils Schröter,Peter Riederer,Paul Lingor +9 more
TL;DR: In this article , the authors summarize the knowledge on blood-based PD biomarkers and present both a researcher's and a clinician's perspective on recent developments and potential future applications.
References
More filters
Journal ArticleDOI
Clinical diagnostic criteria for dementia associated with Parkinson's disease.
Murat Emre,Dag Aarsland,Dag Aarsland,Richard G. Brown,David J. Burn,Charles Duyckaerts,Yoshikino Mizuno,Gerald A. Broe,Jeffrey L. Cummings,Dennis W. Dickson,Serge Gauthier,Jennifer G. Goldman,Christopher G. Goetz,Arnos Korczyn,Andrew J. Lees,Richard Levy,Irene Litvan,Ian G. McKeith,Warren Olanow,Werner Poewe,Niall Quinn,Christina Sampaio,Eduardo Tolosa,Bruno Dubois +23 more
TL;DR: Clinical diagnostic criteria for probable and possible PD‐D are proposed, characterized by impairment in attention, memory, executive and visuo‐spatial functions, behavioral symptoms such as affective changes, hallucinations, and apathy are frequent.
Journal ArticleDOI
Diagnostic Criteria for Mild Cognitive Impairment in Parkinson’s Disease: Movement Disorder Society Task Force Guidelines
Irene Litvan,Jennifer G. Goldman,Alexander I. Tröster,Ben Schmand,Daniel Weintraub,Ronald C. Petersen,Brit Mollenhauer,Charles H. Adler,Karen Marder,Caroline H. Williams-Gray,Dag Aarsland,Jaime Kulisevsky,Maria C. Rodriguez-Oroz,David J. Burn,Roger A. Barker,Murat Emre +15 more
TL;DR: These diagnostic criteria will support future research efforts to identify at the earliest stage those PD patients at increased risk of progressive cognitive decline and dementia who may benefit from clinical interventions at a predementia stage.
Journal ArticleDOI
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson,Ronald Lautner,Ulf Andreasson,Annika Öhrfelt,Erik Portelius,Maria Bjerke,Maria Bjerke,Mikko Hölttä,Christoffer Rosén,Caroline Olsson,Gabrielle Strobel,Elizabeth Wu,Kelly Dakin,Max Petzold,Max Petzold,Kaj Blennow,Henrik Zetterberg,Henrik Zetterberg +17 more
TL;DR: The core CSF biomarkers of neurodegeneration (T-tau, P-tAU, and Aβ42), CSF NFL, and plasma T-t Tau were strongly associated with Alzheimer's disease and the core biomarkers were strong associated with mild cognitive impairment due to Alzheimer's Disease.
Journal ArticleDOI
Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.
TL;DR: This review on the role of neurofilaments as surrogate markers for axonal degeneration in neurological diseases provides a brief background to protein synthesis, assembly, function and degeneration.
Journal ArticleDOI
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis
Claire Bridel,van Wieringen Wn,Henrik Zetterberg,Betty M. Tijms,Charlotte E. Teunissen,José C. Álvarez-Cermeño,Ulf Andreasson,Markus Axelsson,David Bäckström,Ales Bartos,Maria Bjerke,Kaj Blennow,Kaj Blennow,A. Boxer,Lena Brundin,Joachim Burman,Tove Christensen,Lenka Fialová,Lars Forsgren,Jette L. Frederiksen,Magnus Gisslén,Elizabeth Gray,Martin Gunnarsson,Sara Hall,Oskar Hansson,Megan K. Herbert,Joel Jakobsson,Jessen-Krut J,Shorena Janelidze,Gudmundur Johannsson,Gudmundur Johannsson,Michael Jonsson,Ludwig Kappos,Mohsen Khademi,Mohsen Khademi,Michael Khalil,Jens Kuhle,Mikael Landén,Leinonen,Giancarlo Logroscino,Lu Ch,Jan Lycke,Nadia K. Magdalinou,Andrea Malaspina,Niklas Mattsson,Lieke H.H. Meeter,Mehta,Signe Modvig,Tomas Olsson,Tomas Olsson,Ross W. Paterson,Pérez-Santiago J,Fredrik Piehl,Fredrik Piehl,Pijnenburg Yal,Pyykkö Ot,Ragnarsson O,Julio C. Rojas,Romme Christensen J,Sandberg L,Carole Scherling,Jonathan M. Schott,Finn Sellebjerg,Isabella Laura Simone,Tobias Skillbäck,Stilund M,Peter Sundström,Anders Svenningsson,Rosanna Tortelli,Carla Tortorella,Alessandro Trentini,Troiano M,Martin R Turner,van Swieten Jc,Mattias Vågberg,Marcel M. Verbeek,Luisa M. Villar,Pieter Jelle Visser,Pieter Jelle Visser,Anders Wallin,Weiss A,Carsten Wikkelsö,Edward J. Wild +82 more
TL;DR: The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC, and has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.
Related Papers (5)
Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders
Bob Olsson,Bob Olsson,Erik Portelius,Erik Portelius,Nicholas C. Cullen,Nicholas C. Cullen,Åsa Sandelius,Henrik Zetterberg,Ulf Andreasson,Ulf Andreasson,Kina Höglund,Kina Höglund,David J. Irwin,Murray Grossman,Daniel Weintraub,Daniel Weintraub,Alice Chen-Plotkin,David A. Wolk,Leo McCluskey,Lauren Elman,Leslie M. Shaw,Jon B. Toledo,Jon B. Toledo,Jennifer D. McBride,Pilar Hernandez-Con,Virginia M.-Y. Lee,John Q. Trojanowski,Kaj Blennow,Kaj Blennow +28 more